See below for an infographic using data shared in our whitepaper entitled Trends and Considerations on Global Cardiovascular Drug Development.
Cardiovascular agents make up the second largest pipeline – 351 cardiovascular and 258 hypolipaemic/anti-atherosclerosis agents.
Of the 46 cardiovascular diseases specified by the WHO coding system – 65 percent of all CV clinical trials in the 2000s have been in six indications. The top three being: hypertension (27 percent of trials); congestive heart failure (13 percent) and cerebrovascular disease (12 percent).
The U.S Food and Drug Administration approved only 49 novel chemical entities and biologics indicated for CVDs between 2000-2009, compared to 74 between 1990-1999.